Metal-free nitro-carbocyclization of activated alkenes: a direct approach to synthesize oxindoles by cascade C–N and C–C bond formation
作者:Tao Shen、Yizhi Yuan、Ning Jiao
DOI:10.1039/c3cc47336h
日期:——
A novel and direct metal-free nitro-carbocyclization of activatedalkenes leading to valuable nitro-containing oxindoles via cascade C-N and C-C bond formation has been developed. The mechanistic study indicates that the initial NO and NO2 radical addition and the following C-H functionalization processes are involved in this transformation.
Palladium-Catalyzed Oxidative Arylalkylation of Activated Alkenes: Dual CH Bond Cleavage of an Arene and Acetonitrile
作者:Tao Wu、Xin Mu、Guosheng Liu
DOI:10.1002/anie.201104575
日期:2011.12.23
but two: The title reaction proceeds through the dual CHbondcleavage of both aniline and acetonitrile (see scheme). The reaction affords a variety of cyano‐bearing indolinones in excellent yield. Mechanistic studies demonstrate that this reaction involves a fast arylation of the olefin and a rate‐determining CH activation of the acetonitrile.
Ag-Promoted Azido-Carbocyclization of Activated Alkenes via CH Bond Cleavage
作者:Yizhi Yuan、Tao Shen、Kui Wang、Ning Jiao
DOI:10.1002/asia.201300960
日期:2013.12
silver‐promoted azido‐carbocyclization of activatedalkenesvia a radical pathway has been developed. Azido oxindoles, which hold great potential for subsequent transformation of the azido unit, are efficiently constructed by this protocol. Radical addition and CH functionalization processes are involved in this transformation with the formation of CN and CC bonds. Silver is observed to promote the
[EN] INHIBITORS OF THE EGF-RECEPTOR TYROSINE KINASE AND THEIR USE<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DU RECEPTEUR DE L'EGF ET LEURS UTILISATIONS
申请人:PARKER HUGHES INST
公开号:WO2000056703A1
公开(公告)日:2000-09-28
Novel compounds and pharmaceutical compositions useful as EGFR tyrosine kinase inhibitors. Methods of the invention include administration of the EGFR TK inhibitors to treat diseases characterized by enhanced expression of EGF, including cancers, particularly breast cancer. Additionally, a homology model representing the structure of EGFR kinase domain is provided, which model is useful for the rationally design and screening of compounds predicted to bind favorably to EGFR and to inhibit EGFR TK.